Portico and Navitor India Clinical Trial

Inclusion Criteria:

1. Subject must provide written informed consent prior to any clinicalinvestigation-related procedure.

2. Are >60 years of age in host country, have severe symptomatic (NYHA class ≥ II)aortic stenosis (AS), at high or extreme surgical risk and have been identified as acandidate for a Portico or Navitor valve implant.

3. Subjects must have a Society of Thoracic Surgeons (STS) score of ≥7% OR documentedheart team agreement of high or extreme risk for surgical aortic valve replacementdue to frailty or co-morbidities not captured by the STS score.

Exclusion Criteria:

1. Have tested positive for the Corona Virus Disease 2019 (COVID-19) virus at any timeAND currently have residual signs or symptoms associated with the COVID-19 virus (eg. evidence of thrombosis, damaged/inflamed heart muscle, damaged/inflamed lungtissue, etc.)

2. Have sepsis, including active endocarditis

3. Have any evidence of left ventricular or atrial thrombus

4. Have vascular conditions (i.e. caliber, stenosis, tortuosity, or severecalcification) that make insertion and endovascular access to the aortic valveimprobable

5. Have a non-calcified aortic annulus

6. Have congenital bicuspid or unicuspid leaflet configuration

7. Are unable to tolerate antiplatelet/anticoagulant therapy

8. Are pregnant at the time of signing informed consent

9. Are currently participating in a drug or device study that may impact this study (unless prior sponsor approval for co-enrollment is granted)